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Abstract
Background: Metabolic tumor volume assessment using positron-emission tomography [PET] may be of interest
for both target volume definition in radiotherapy and monitoring response to therapy. It has been reported,
however, that metabolic volumes derived from images of metabolic rate of glucose (generated using Patlak
analysis) are smaller than those derived from standardized uptake value [SUV] images. The purpose of this study
was to systematically compare metabolic tumor volume assessments derived from SUV and Patlak images using a
variety of (semi-)automatic tumor delineation methods in order to identify methods that can be used reliably on
(whole body) SUV images.
Methods: Dynamic [18F]-fluoro-2-deoxy-D-glucose [FDG] PET data from 10 lung and 8 gastrointestinal cancer
patients were analyzed retrospectively. Metabolic tumor volumes were derived from both Patlak and SUV images
using five different types of tumor delineation methods, based on various thresholds or on a gradient.
Results: In general, most tumor delineation methods provided more outliers when metabolic volumes were
derived from SUV images rather than Patlak images. Only gradient-based methods showed more outliers for Patlak-
based tumor delineation. Median measured metabolic volumes derived from SUV images were larger than those
derived from Patlak images (up to 59% difference) when using a fixed percentage threshold method. Tumor
volumes agreed reasonably well (< 26% difference) when applying methods that take local signal-to-background
ratio [SBR] into account.
Conclusion: Large differences may exist in metabolic volumes derived from static and dynamic FDG image data.
These differences depend strongly on the delineation method used. Delineation methods that correct for local SBR
provide the most consistent results between SUV and Patlak images.
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Background
Positron-emission tomography [PET] may be used to
delineate the biological target volume for both radio-
therapy and response monitoring purposes [1-4]. The
most widely used PET tracer, [18F]-fluoro-2-deoxy-D-
glucose [FDG], might improve accuracy of tumor
volume definition for radiotherapy by identifying areas
within the tumor that are more metabolically active [5].
Tumor volumes can be delineated on either images of
glucose metabolic rate or standardized uptake value
[SUV] images [6]. SUV is most commonly used for
(semi-)quantification of whole-body FDG PET studies
and only requires a static scan. Images of glucose meta-
bolic rate can be generated from dynamic scans using a
measured or image-derived arterial input function
together with Patlak graphical analysis. It is well known
that Patlak analysis is quantitatively more accurate than
SUV analysis. Patlak analysis, however, requires a
dynamic scan and limits data acquisition to a single bed
position with an axial coverage of < 20 cm.
As shown previously [6], metabolic volumes, defined
using a 50% isocontour method, were smaller when
defined on Patlak images than when defined on SUV
images. To date, however, no systematic comparison has
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been performed in which various existing (semi-)auto-
matic tumor delineation methods have been applied to
both SUV and Patlak images.
Recently, a number of different (semi-)automatic tumor
delineation methods have been validated for SUV images
using both simulations [7,8] and lung tumor FDG scans
[9,10]. Most methods showed good performance as mea-
sured maximum diameters derived from these methods
corresponded well with pathological measurements [11].
As most of tumor delineation methods that correct for
local background are less sensitive to changes in local con-
trast, these methods might show better correspondence
between measured tumor volumes derived from either
Patlak or SUV images. Therefore, the purpose of this
study was to systematically compare measured metabolic
tumor volumes derived from SUV and Patlak images
using a variety of (semi-)automatic tumor delineation
methods.
Materials and methods
Patient data
Dynamic FDG PET scans from 10 non-small cell lung
cancer [NSCLC] (stages IIIB to IV) patients [12] and 8
gastrointestinal [GI] (colorectal carcinoma) cancer patients
[13] were included retrospectively. All scans had been
acquired prior to therapy. All patients had given written
informed consent, and both studies had been approved by
the Medical Ethics Review Committee of the VU Univer-
sity Medical Center.
For NSCLC patients (three females, seven males; weight
76 ± 10 kg, range 56 to 94 kg), blood glucose levels were
within the normal range (mean 5.5 ± 0.6 mmol·L-1, range
4.4 to 7.0 mmol·L-1). The same was true for blood glucose
levels (mean 5.6 ± 0.8 mmol·L-1, range 3.9 to 7.0 mmol·L-1)
of patients with advanced GI malignancies (one female,
seven males; weight 85 ± 15 kg, range 60 to 110 kg).
PET scanning protocol
All patients fasted for at least 6 h before scanning.
Patients were prepared in accordance with recently pub-
lished guidelines for quantitative PET studies [14]. They
were scanned in a supine position and received an intra-
venous catheter for tracer administration. During
dynamic scanning, blood samples for determining plasma
glucose levels were collected at fixed times (i.e., at 35, 45,
55 min post injection). All dynamic scans were per-
formed using an ECAT EXACT HR+ scanner (Siemens/
CTI, Knoxville, TN, USA) [15], having a 15.5-cm axial
field of view. Each scan session started with a 10-min
transmission scan using three retractable rotating 68Ge
line sources. After completion of the transmission scan, a
bolus of FDG was administrated intravenously (388 ± 71
and 459 ± 97 MBq for NSCLC and GI cancer, respec-
tively), at the same time starting a dynamic emission scan
in a 2-D acquisition mode. Each dynamic scan consisted
of 40 frames with the following lengths, 1 × 30, 6 × 5, 6 ×
10, 3 × 20, 5 × 30, 5 × 60, 8 × 150, 6 × 300 s. In addition,
a static scan was created by summing the sinograms of
the last three frames (i.e., 45 to 60 min post injection).
All data were normalized and corrected for attenua-
tion, random coincidences, scatter radiation, dead time,
and decay. Reconstructions were performed using nor-
malization and attenuation-weighted ordered subsets
expectation maximization [OSEM] with 2 iterations and
16 subsets, followed by post-smoothing using a 0.5 Han-
ning filter. This resulted in an image resolution of
approximately 6.5 mm full width at half maximum. An
image matrix size of 256 × 256 × 63 was used, corre-
sponding to a pixel size of 2.57 × 2.57 × 2.43 mm3.
After reconstruction, the summed image (45 to 60
min post injection) was used to generate a SUV image
by normalizing local tissue concentrations to injected
dose and body weight. In addition, Patlak analysis, a
kinetic linearized model [16] for irreversible tracer
uptake, was applied to the interval 10 to 60 min post
injection to generate an image of net influx rate [Ki] of
FDG, which is proportional to the metabolic rate of glu-
cose. Image-derived input functions [IDIF] were used as
plasma input curves and obtained as described by
Cheebsumon et al. [17]. In short, 3-D volumes of inter-
est [VOI] were drawn manually in three vascular struc-
tures (i.e., the left ventricle, aortic arch, and ascending
aorta) using an early frame that highlights the blood
pool [18]. These VOI were then projected onto all
frames yielding arterial whole blood time activity curves
(i.e., IDIF). The average input curves from VOI defined
in the three vascular structures were used as an input
function during Patlak analysis.
Data analysis
For the 10 NSCLC patients, VOI were defined for 54
lesions that were all located in the lung. For the 8 GI
cancer patients, VOI were defined for 37 lesions that
were located in the liver (n = 23), lung (n = 12), or
colon (n = 2). All lesions that could be identified by an
expert physician were included in this study. Metabolic
tumor volumes were obtained using the following five
different types of (semi-)automatic VOI methods:
Fixed threshold of 50% and 70% (VOI50, VOI70). In
this method, a fixed threshold (i.e., 50% or 70%) of the
maximum voxel value within a tumor is used to deline-
ate the tumor [19].
Adaptive threshold of 41%, 50%, and 70% (VOIA41,
VOIA50, VOIA70). This is similar to the fixed threshold
method, except that it adapts the threshold relative to
the local average background, thereby correcting for
the contrast between the tumor and local background
[19].
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Contrast-oriented method (VOISchaefer). This method
uses the average of SUV within a 70% threshold of
SUVmax isocontour (meanSUV70%) and background
activity for various sphere sizes. Regression coefficients
are calculated, which represent the relationship between
the optimal threshold and image contrast for various
sphere sizes [3]. This threshold equation is given by:
Thresholdoptimal = A×meanSUV70% + B× Background,
where A and B are fitted using phantom studies [3].
When applied to Patlak images, Ki rather than SUV
is used. In general, different values are applied for
sphere diameters smaller and larger than 3 cm in
diameter. In the present study, this method was reca-
librated, i.e., specific A and B values for the image
characteristics used were determined.
Background-subtracted relative-threshold level [RTL]
method (VOIRTL). This method is an iterative method
that is based on a convolution of the point-spread func-
tion, which takes into account differences between var-
ious sphere sizes and the scanner resolution [4].
Gradient-based watershed segmentation method. This
method uses two steps before calculating the VOI [2].
First, a gradient image is calculated on which a ‘seed’ is
placed in the tumor (tumor basin) and another in the
background (background basin). Next, a watershed
[WT] algorithm is used to grow both seeds in the gradi-
ent basins, thereby creating boundaries on the gradient
edges. In the present study, two different types of gradi-
ent basins were used. In the first approach [GradWT1],
all voxels on the edge between the tumor and back-
ground are assigned to the tumor [8,10]. In the second
approach [GradWT2], an upsampled image is used to
ensure less effects of sampling. In addition, a voxel on
the edge between the tumor and background is allocated
to either the tumor or background based on the smallest
difference with that voxel value.
To reduce sensitivity to noise, for all methods, the
maximum voxel value was obtained using a cross-
shaped pattern. This method searches for the region
with the (local) average maximum intensity based on
the average of seven neighboring voxels, which was then
used as a maximum or ‘peak’ value. The tumor-to-back-
ground ratio was calculated by dividing this maximum
value by the background value surrounding the tumor.
Statistical analyses
Both metabolic volumes and differences in measured
volumes derived from two image types are reported.
The percentage volume difference was defined as(
VolumeSUV
VolumePatlak
- 1
)
× 100% . Note that this value can
be negative, indicating an underestimation of the SUV-
derived metabolic volume compared with the Patlak-
derived volume. In addition, for each delineation
method, mean, median, first quartile, third quartile,
minimum, and maximum values, including statistical
outliers, are reported in box plots. Moreover, visual out-
liers were identified as VOIs that showed unrealistically
large or small volumes when compared visually with the
tumor. These outliers were not included in the statistical
analysis when calculating p values. A two-tailed Wil-
coxon signed-rank test was used to indicate statistically
significant differences between measured volumes
derived from SUV and Patlak images, where p values
less than 0.05 were considered to be significant.
Results
Table 1 shows the number of visual outliers (i.e., those
cases where there is an obvious mismatch between
derived VOI and tumor boundaries) for all methods
applied to both Patlak and SUV images, specifying
results for NSCLC and GI cancer separately. In general,
most tumor delineation methods provided more outliers
when metabolic volumes were derived from SUV images
rather than Patlak images. Only gradient-based methods
showed more outliers for Patlak-based tumor delinea-
tion. VOI70 and VOIA70 provided no outliers for either
image or cancer type.
In general, measured tumor volumes derived from SUV
images were larger than those derived from Patlak images.
Example images of the measured tumor volumes derived
from SUV and Patlak images are shown in Figure 1.
Exceptions were VOIA70 for both types of cancer and the
two gradient-based methods for GI cancer (Tables 2 and
3). Large differences (up to 58.7% and 28.1% for NSCLC
and GI cancer, respectively) in measured metabolic
volume based on the two image types were observed for
Table 1 Number of visual outliers in SUV- and Patlak-
derived measured metabolic volumes for both cancer
Delineation
method
NSCLC GI cancer
SUV
image
Patlak
image
SUV
image
Patlak
image
VOI50 9 - 5 3
VOI70 - - - -
VOIA41 4 1 5 3
VOIA50 - - - 1
VOIA70 - - - -
VOIRTL - 1 3 -
VOISchaefer 2 2 3 2
GradWT1 - 3 13 15
GradWT2 2 5 5 5
NSCLC, non-small cell lung cancer; GI, gatrointestinal; SUV, standardized
uptake value; VOI, volumes of interest; GradWT1, gradient-based watershed first
approach; GradWT2, gradient-based watershed second approach.
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Figure 1 Coronal images of the measured tumor volumes. Coronal images of the measured tumor volumes derived from SUV and Patlak
images of one patient with NSCLC, obtained using four different tumor delineation methods (i.e., VOI50, VOIA50, GradWT1, and GradWT2).
Table 2 Mean, median, minimum, and maximum values of metabolic volumes and their median differences for NSCLC
Delineation method Volume obtained from SUV image
(mL)
Volume obtained from Patlak image
(mL)
% Median differencea P value P valueb
Mean Median Min Max Mean Median Min Max
VOI50 84.2 6.9 1.2 950.2 7.7 2.7 0.7 74.4 58.7 < 0.001 < 0.001
VOI70 4.9 1.5 0.5 50.2 2.5 1.1 0.3 23.7 48.0 < 0.001 < 0.001
VOIA41 22.7 5.2 1.2 294.4 10.9 3.5 0.9 95.2 25.8 < 0.001 < 0.001
VOIA50 8.8 2.4 0.6 97.0 6.6 2.4 0.5 70.6 15.0 < 0.001 < 0.001
VOIA70 2.1 0.5 0.1 23.4 1.8 0.8 0.2 19.9 -25.0 0.044 0.044
VOIRTL 10.4 3.6 0.4 101.9 7.7 3.1 0.3 73.1 15.6 < 0.001 < 0.001
VOISchaefer 17.2 5.1 1.0 125.7 13.8 4.2 0.9 104.2 14.3 < 0.001 < 0.001
GradWT1 12.3 3.9 1.4 163.2 10.4 5.4 1.6 50.9 1.9 0.725 0.324
GradWT2 5.8 2.7 0.6 63.2 3.7 2.1 0.5 28.2 18.2 < 0.001 0.001
aThe percentage difference was defined as
(
VolumeSUV
VolumePatlak
- 1
)
× 100% . The average tumor-to-background ratio was 5.3 (range 2.7 to 12.7) and 18.8
(range 6.1 to 81.0) when derived from SUV and Patlak images, respectively. bWithout visual outliers. SUV, standardized uptake value; min, minimum; max,
maximum; VOI, volumes of interest; GradWT1, gradient-based watershed first approach; GradWT2, gradient-based watershed second approach.
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the various delineation methods (Figure 2A). In the case of
NSCLC, the median difference in volume was higher for
fixed threshold methods than for adaptive, contrast-
oriented, or gradient-based methods. This is further illu-
strated by Figure 3A, where VOIA50 (i.e., with background
correction) shows better correspondence between SUV-
and Patlak-based volumes than VOI50 (i.e., without back-
ground correction). Only GradWT1 provided no significant
difference (p > 0.05) in the metabolic volume derived from
SUV and Patlak images, but this may be due to the large
spread in differences (Figure 3B). Similar results were
found when these differences in volume were compared to
SUV (or Ki values, Figures 4A, B). In general, we observed
that smaller lesions also had the lowest SUV. Conse-
quently, the largest volume differences between SUV and
Patlak image-based tumor delineations were seen for
lesions having a low SUV and a small metabolic volume.
Similar trends were observed for GI cancer (Figures 2B
and 3C, D). Here, GradWT1 (only after removal of visual
outliers), GradWT2, and VOIA50 provided no significant
differences (p > 0.05) between measured volumes derived
from both image types. In addition, similar trends were
observed when data from both studies were pooled and
presented separately for the specific locations of the
tumors (i.e., the liver or the lung, Figure 2C).
Discussion
The main use of FDG is measurement of glucose meta-
bolism. However, FDG PET can also be used to measure
the volume with increased metabolism. In a previous
report [6], it was shown that tumor delineation using
Patlak-derived glucose metabolism images provided
smaller volumes and sharper borders than when SUV
images were used. This was due to a higher local con-
trast in Patlak images than in SUV images. Patlak
analysis, however, may not always be feasible or optimal
because it requires (measured) arterial input data and a
dynamic scan, which limits coverage to a single bed
position. Therefore, in clinical practice, a static whole-
body scan (covering the whole body) might be preferred,
in which case data can only be analyzed using a SUV
approach. It is well known, however, that SUV may be
affected by technical, biological, and physical factors
[20] that could hamper tumor delineation using this
image type.
In agreement with Visser et al. [6], the present study
showed (for two types of cancer) that when a fixed percen-
tage threshold method (i.e., VOI50) was used, significantly
larger metabolic volumes were obtained from SUV images
than from Patlak images. However, these differences
reduced when using methods that correct for local back-
ground and/or contrast, and in the case of gradient-based
methods (Figure 2, Tables 2 and 3). This confirms that
SUV-based tumor delineation is sensitive to signal-to-
background ratios. Differences in Patlak- and SUV-derived
volumes were larger for NSCLC than for GI cancer, espe-
cially in the case of methods that use a fixed percentage
threshold without background correction. As local (image)
contrast for GI cancer was larger than that for NSCLC
(average tumor-to-background ratios 7.4 and 5.3, respec-
tively), this further illustrates the sensitivity to signal-to-
background ratio.
Some tumor delineation methods (i.e., VOI50, VOIA41,
and GradWT1) provided visually, unrealistically large
tumor volumes (in up to 41% of cases) when applied to
SUV images, while VOISchaefer did the same (in up to
8% of cases) for both image types (Table 1). In contrast,
GradWT2 provided many unrealistically small tumor
volumes (in up to 24% of cases) for both image types.
This suggests that these methods should be applied
Table 3 Mean, median, minimum, and maximum values of metabolic volumes and median differences for GI cancer
Delineation method Volume obtained from SUV image
(mL)
Volume obtained from Patlak image
(mL)
% Median differencea P value P valueb
Mean Median Min Max Mean Median Min Max
VOI50 190.4 15.4 2.7 2297.8 65.2 10.1 2.1 822.9 28.1 < 0.001 < 0.001
VOI70 10.5 3.9 1.3 57.6 8.8 3.5 1.0 45.2 18.5 < 0.001 < 0.001
VOIA41 195.4 28.6 3.3 2402.5 86.1 11.9 2.5 1257.6 16.5 < 0.001 < 0.001
VOIA50 20.3 6.0 2.1 121.2 22.2 6.8 1.9 107.3 8.1 0.364 0.215
VOIA70 5.1 1.7 0.7 38.8 6.57 2.38 0.51 34.26 -13.3 0.001 0.001
VOIRTL 33.3 7.2 0.3 538.2 17.78 6.75 0.26 111.14 7.5 0.040 0.042
VOISchaefer 158.0 14.7 3.4 2212.0 48.1 13.0 2.5 564.6 8.3 0.003 0.004
GradWT1 43.5 32.8 9.1 223.5 51.2 43.2 10.2 229.4 -9.1 0.025 0.085
GradWT2 12.4 6.8 1.5 74.1 14.2 8.6 1.6 85.3 -2.1 0.625 1.000
aThe percentage difference was defined as
(
VolumeSUV
VolumePatlak
- 1
)
× 100% . The average tumor-to-background ratio was 7.4 (range 2.4 to 31.6) and 16.0
(range 3.0 to 32.0) when derived from SUV and Patlak images, respectively. bWithout visual outliers. SUV, standardized uptake value; min, minimum; max,
maximum; VOI, volumes of interest; GradWT1, gradient-based watershed first approach; GradWT2, gradient-based watershed second approach.
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carefully and that their performance should be
supervised.
Two different implementations of gradient-based
methods were evaluated in the present study. In a pre-
vious NSCLC study [11], tumor diameters obtained
using GradWT2 corresponded better to pathology than
those obtained using GradWT1. As shown in Figure 3B,
the present study also showed that measured volumes
obtained from GradWT2 were smaller than those from
GradWT1. However, GradWT1 showed better correspon-
dence between SUV- and Patlak-derived volumes than
GradWT2 (1.9% and 18.2%, respectively). In contrast, for
GI cancer, GradWT2 showed better correspondence
between SUV- and Patlak-derived volumes than
GradWT1 (-2.1% and -9.1%, respectively). This suggests
that the performance of gradient-based methods may
also depend on signal-to-background ratios.
Differences between metabolic volumes obtained from
SUV and Patlak images reduced when signal-to-back-
ground-corrected delineation methods are used. This
finding is in line with previous studies reporting on test-
retest variability using various tumor delineation
Figure 2 Box-and-whisker plots of the percentage differences between measured volumes derived from SUV and Patlak images. Box-
and-whisker plots of the percentage differences between measured volumes derived from SUV and Patlak images for different tumor
delineation methods in (A) NSCLC and (B) GI cancer, and (C) the pooled data from both studies specified per location, i.e., the liver and the
lung. The median is the horizontal line between the lower (first) and upper (third) quartiles. Empty square represents the average value, cross,
the minimum and maximum values, and filled left-pointing pointer, the number of statistical outliers. The percentage difference was defined as(
VolumeSUV
VolumePatlak
- 1
)
× 100% .
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methods [10,21] that confirmed that VOIA50 seems to
be a good possible candidate for response monitoring
purposes. However, gradient-based methods have been
shown to be good candidates for radiotherapy purposes
[10,22]. Therefore, either signal-to-background-corrected
or gradient-based methods may be good candidates for
response assessments and radiotherapy purposes.
Limitations
A limitation of this study is the lack of an independent
reference standard to define tumor volumes, and conse-
quently, in this paper, we could only study differences in
(semi-)automatic tumor delineation method perfor-
mance when applied onto Patlak versus SUV images.
However, the accuracy and precision of several (semi-)
automatic tumor delineation methods have been studied
previously using simulations [8] and clinical test-retest
data [10]. Both articles showed that performance of
tumor delineation methods are affected by several fac-
tors, such as scanner type, radiotracer, image noise, and
tumor characteristics. It is generally accepted that
pathology is the gold standard. Therefore, studies are
needed and are currently performed that compare the
tumor volumes obtained using (semi-)automatic delinea-
tion methods with pathology [11].
Although the Patlak analysis was performed on OSEM-
reconstructed images in order to reduce the levels of
noise, Patlak images still showed a small fraction (< 1%)
of voxels that had a negative slope, exclusively seen in
non-tumor tissue locations. Correlation-coefficient
Figure 3 Percentage difference in measured volumes compared to the measured volume. Percentage difference in measured volumes
compared to the measured volume derived from SUV and Patlak images for various delineation methods applied to (A, B) NSCLC and (C, D) GI
cancer. Note that some data points (for VOI50 and GradWT2) fall outside the range of the figure. The percentage difference was defined as(
VolumeSUV
VolumePatlak
- 1
)
× 100% .
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filtered parametric imaging, as proposed by Zasadny and
Wahl [23], could potentially enhance the quality of the
Patlak images and could be further investigated to
improve the accuracy of automated tumor delineation.
Despite the lack of using such a denoising method, our
results were in line with those published by Visser et al.
[6], and we could identify that tumor delineation meth-
ods that correct for local signal-to-background contrast
or use gradients showed a better agreement in tumor
volume assessment between Patlak and SUV images than
those tumor delineation methods that did not.
Conclusion
Large differences may exist in metabolic volumes
derived from static (SUV) and dynamic (Patlak) FDG
image data. These differences depend strongly on the
delineation method used. (Semi-)automatic tumor deli-
neation methods that correct for local signal-to-back-
ground contrast or use gradients provide the most
consistent results between SUV and Patlak images.
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